抗精神病药物市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

抗精神病药物市场按应用(精神分裂症、双相情感障碍、单相抑郁症、痴呆症等)、药物分类和地理细分

市场快照

Antipsychotic Drugs Market Overview
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 3.5 %
Antipsychotic Drugs Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

精神疾病(如精神分裂症和双相情感障碍)在人群中患病率的上升是市场的主要增长动力。根据美国焦虑症和抑郁症协会的数据,焦虑症是美国最常见的精神疾病,每年影响美国 4000 万 18 岁及以上的成年人,占人口的 18.1%。近一半被诊断患有抑郁症的人也被诊断出患有焦虑症。

世界卫生组织 (WHO) 提出了精神卫生行动计划,以促进成员国的精神健康和预防精神障碍。此外,根据世界卫生组织公布的关键事实,全世界估计有 3 亿人受到抑郁症的影响,6000 万人受到双相情感障碍的影响。焦虑症是影响儿童和成人的最常见的精神疾病。据估计,有 4400 万美国成年人受到不安问题的影响。仅仅,大约三分之一的焦虑症患者接受了治疗,尽管这些疾病是高度可治疗的。

因此,表明市场将主要受到精神障碍患病率上升的推动。

报告范围

抗精神病药物是用于治疗包括精神分裂症和双相情感障碍在内的精神病的药物。

By Application
Schizophrenia
Bipolar Disorder
Unipolar Disorder
Dementia
Others
By Drug Classification
First Generation (Typical)
Second Generation (Atypical)
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

精神分裂症有望在预测期内实现良好的复合年增长率

精神分裂症是一种严重的精神障碍,正在影响全球大量人群。这种疾病的主要特征是思维、情绪、自我意识和行为的扭曲。世界卫生组织表示,全球约有 2300 万人受到这种疾病的影响,其中男性 1200 万人,女性 900 万人。美国国家心理健康研究所表示,精神分裂症及相关症状的患病率约为 0.25% 和 0.64%,并且正在迅速增加。这种疾病流行率的上升促进了市场的增长。

由于这种疾病很严重,如果治疗不当,会增加早逝的机会,因此越来越多的公司将注意力集中在开发治疗这种疾病的新药上。目前,市场上有几种 FDA 批准的药物。如氯丙嗪、阿立哌唑、奥氮平等,每年都有新药获批,预计将在预测期内带动市场增长。

Antipsychotic Drugs Market key Trends

预计北美将在预测期内主导市场

由于完善的医疗保健基础设施、更好的监管框架以及该地区国家的政府支持,预计北美将主导市场份额。然而,预计亚太地区将在预测期内出现最快的增长率。由于社会对精神病和其他相关疾病(如躁狂症、焦虑症和抑郁症)的认识不断提高,预计健康的复合年增长率将达到。用于治疗精神疾病的药物的日益普及和供应预计将推动市场的增长。

Antipsychotic Drugs Market Growth Rate

竞争格局

抗精神病药物市场竞争适度,由全球参与者和本地参与者组成。由于大多数治疗该疾病的药物都获得了美国 FDA 的批准,因此全球参与者目前占据了主要市场份额。由于小企业越来越重视市场渗透,相信这些企业在未来将占据相当大的市场份额。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Mental Disorders

      2. 4.2.2 Increasing Focus of Governments and Health Care Organizations on Mental Health

      3. 4.2.3 Constant Investment in Research and Development

    3. 4.3 Market Restraints

      1. 4.3.1 Addiction Caused Due to the Antipsychotic Drugs

      2. 4.3.2 Patent Expiry of Major Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Application

      1. 5.1.1 Schizophrenia

      2. 5.1.2 Bipolar Disorder

      3. 5.1.3 Unipolar Disorder

      4. 5.1.4 Dementia

      5. 5.1.5 Others

    2. 5.2 By Drug Classification

      1. 5.2.1 First Generation (Typical)

      2. 5.2.2 Second Generation (Atypical)

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Eli Lily and Company

      2. 6.1.2 AstraZeneca plc

      3. 6.1.3 GlaxoSmithKline plc

      4. 6.1.4 Johnson & Johnson

      5. 6.1.5 Otsuka Pharmaceutical Co, Ltd.

      6. 6.1.6 Pfizer Inc.

      7. 6.1.7 AbbVie Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Antipsychotic Drugs Market market is studied from 2018 - 2026.

The Antipsychotic Drugs Market is growing at a CAGR of 3.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Eli Lily and Company, Johnson and Johnson, Pfizer Inc., AstraZeneca plc, Otsuka Pharmaceutical Co, Ltd. are the major companies operating in Antipsychotic Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!